Globeimmune Inc.
Globeimmune Inc. is listed today as Globeimmune, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2017 | $2 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jan 2014 | $8 M | No. 4 | $2 to $10 million | debt, options | SEC | |
| Jan 2010 | $18 M | No. 3 | $10 to $50 million | equity | SEC | |
| May 2009 | $13 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Mar 2009 | $3 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Globeimmune Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2017).
SEC Form D · Mar 2017
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2017
That is all the official record says: Globeimmune Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Globeimmune Inc. are on record.
Investors#
6 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Celgene Corp /de/ | Company | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Celgene International Inc | Company | not stated | not stated | Held Series C, D and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| HealthCare Partners VII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Healthcare Ventures VII LP | Venture capital | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Morgenthaler Management Partners VII, LLC | Fund or asset manager | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Morgenthaler Partners VII LP | Fund or asset manager | not stated | not stated | Held Series A, B, C and E preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 110 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| C. Jeffrey Dekker | Executive officer | Mar 2017 |
| C Jeffrey Dekker | Executive officer | Jun 2014 |
| Kirk A Christoffersen | Executive officer | Jun 2014 |
| Timothy C Rodell | Executive officer | Jun 2014 |
| David C Apelian | Executive officer | Feb 2010 |
| Jeff C Rona | Executive officer | Feb 2010 |
| John C Frenz | Executive officer | Feb 2010 |
| David Apelian | Executive officer | May 2009 |
| Jeff Rona | Executive officer | May 2009 |
| John Frenz | Executive officer | May 2009 |
| Charles Jeffrey Kim | Director | Mar 2017 |
| Jerel Jeffrey Banks | Director | Mar 2017 |
| Timothy C. Rodell | Director | Mar 2017 |
| Augustine J Lawlor | Director | Jun 2014 |
| Dan J Mitchell | Director | Jun 2014 |
| J William Freytag | Director | Jun 2014 |
| Paul A Mieyal | Director | Jun 2014 |
| Pennina J Safer | Director | Jun 2014 |
| Ralph E Christoffersen | Director | Jun 2014 |
| S Edward Torres | Director | Jun 2014 |
| Timothy C Rodell | Director | Jun 2014 |
| Augustine William Lawlor | Director | Feb 2010 |
| Darren C Carroll | Director | Feb 2010 |
| Ehud William Geller | Director | Feb 2010 |
| J. William Freytag | Director | Feb 2010 |
| Paul William Mieyal | Director | Feb 2010 |
| Ralph C Christoffersen | Director | Feb 2010 |
| Augustine Lawlor | Director | May 2009 |
| Darren Carroll | Director | May 2009 |
| Ehud Geller | Director | May 2009 |
| Paul Mieyal | Director | May 2009 |
| Ralph Christoffersen | Director | May 2009 |
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.